Post by
francoisl13 on Aug 02, 2023 9:58am
News - strategic review of STEM animal health
Interesting news this morning. This could, if well done, allow KNE to finance their DispersinB development and speed up the dermatology products development without diluting existing shareholders.
Phase 3 trials of DispersinB should start sometimes in Q3.
I also wonder how sales of Coactiv+ are going south of the border...hopefully Progenacare will gain some traction quickly.
GLTA
Comment by
pibopibopibopib on Aug 02, 2023 11:18am
Yes but STEM begin to make money ????
Comment by
RoyMax123 on Aug 02, 2023 11:47am
They are out of cash (or close to) and they owe 5M to Pivot... That also mean that there's no "Big Pharma" willing to put a significant upfront amount for DispersinB Trials, because they would not have to raise money that way if that were the case.
Comment by
RoyMax123 on Aug 02, 2023 2:30pm
BTW, It would be great if they can have a deal where they receive enough cash to clear the debt and survive until the coactiv+ sales are good enough to stop being in red. But maybe I'm asking for too much.